Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Ocugen (NASDAQ:OCGN) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group cut their price target on Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Weiss Ratings downgraded shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Ocugen Stock Performance

NASDAQ OCGN opened at $1.27 on Friday. The company has a market capitalization of $430.67 million, a PE ratio of -4.88 and a beta of 2.21. The company has a debt-to-equity ratio of 4.17, a current ratio of 1.86 and a quick ratio of 1.86. Ocugen has a 1 year low of $0.96 and a 1 year high of $2.73. The company has a fifty day moving average of $1.34 and a two-hundred day moving average of $1.56.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.49 million during the quarter, compared to the consensus estimate of $0.89 million. As a group, analysts expect that Ocugen will post -0.22 earnings per share for the current year.

Insider Activity

In other Ocugen news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were acquired at an average cost of $1.23 per share, for a total transaction of $25,830.00. Following the transaction, the chief financial officer directly owned 521,000 shares of the company’s stock, valued at approximately $640,830. This represents a 4.20% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.95% of the stock is owned by company insiders.

Institutional Trading of Ocugen

Several institutional investors and hedge funds have recently modified their holdings of OCGN. UBS Group AG increased its position in Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock worth $6,547,000 after buying an additional 3,824,474 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Ocugen in the fourth quarter valued at approximately $289,000. Cora Capital Advisors LLC grew its holdings in Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after purchasing an additional 6,500 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Ocugen by 121.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 2,830,397 shares of the company’s stock worth $4,331,000 after purchasing an additional 1,553,672 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in Ocugen by 23.0% during the first quarter. NewEdge Advisors LLC now owns 166,595 shares of the company’s stock worth $302,000 after purchasing an additional 31,135 shares during the period. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.